199 related articles for article (PubMed ID: 32276412)
41. DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders.
Eller-Vainicher C; Falchetti A; Gennari L; Cairoli E; Bertoldo F; Vescini F; Scillitani A; Chiodini I
Eur J Endocrinol; 2019 Apr; ():. PubMed ID: 31042675
[TBL] [Abstract][Full Text] [Related]
42. State of the art in osteoporosis risk assessment and treatment.
Liu J; Curtis EM; Cooper C; Harvey NC
J Endocrinol Invest; 2019 Oct; 42(10):1149-1164. PubMed ID: 30980341
[TBL] [Abstract][Full Text] [Related]
43. Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk.
Muscogiuri G; Barrea L; Altieri B; Di Somma C; Bhattoa HP; Laudisio D; Duval GT; Pugliese G; Annweiler C; Orio F; Fakhouri H; Savastano S; Colao A
Curr Vasc Pharmacol; 2019; 17(6):610-617. PubMed ID: 30963976
[TBL] [Abstract][Full Text] [Related]
44. Nutritional and vitamin status in patients with neuroendocrine neoplasms.
Clement DS; Tesselaar ME; van Leerdam ME; Srirajaskanthan R; Ramage JK
World J Gastroenterol; 2019 Mar; 25(10):1171-1184. PubMed ID: 30886501
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
46. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials.
Keum N; Lee DH; Greenwood DC; Manson JE; Giovannucci E
Ann Oncol; 2019 May; 30(5):733-743. PubMed ID: 30796437
[TBL] [Abstract][Full Text] [Related]
47. The Radiology of Osteoporotic Vertebral Fractures Revisited.
Lentle B; Koromani F; Brown JP; Oei L; Ward L; Goltzman D; Rivadeneira F; Leslie WD; Probyn L; Prior J; Hammond I; Cheung AM; Oei EH;
J Bone Miner Res; 2019 Mar; 34(3):409-418. PubMed ID: 30645770
[TBL] [Abstract][Full Text] [Related]
48. Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis.
Liu J; Li X; Fan L; Yang J; Wang J; Sun J; Wang Z
Life Sci; 2019 Feb; 218():213-223. PubMed ID: 30605646
[TBL] [Abstract][Full Text] [Related]
49. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
[TBL] [Abstract][Full Text] [Related]
50. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.
Cella D; Beaumont JL; Hudgens S; Marteau F; Feuilly M; Houchard A; Lapuerta P; Ramage J; Pavel M; Hörsch D; Kulke MH
Clin Ther; 2018 Dec; 40(12):2006-2020.e2. PubMed ID: 30477789
[TBL] [Abstract][Full Text] [Related]
51. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.
Manson JE; Cook NR; Lee IM; Christen W; Bassuk SS; Mora S; Gibson H; Gordon D; Copeland T; D'Agostino D; Friedenberg G; Ridge C; Bubes V; Giovannucci EL; Willett WC; Buring JE;
N Engl J Med; 2019 Jan; 380(1):33-44. PubMed ID: 30415629
[TBL] [Abstract][Full Text] [Related]
52. European guidance for the diagnosis and management of osteoporosis in postmenopausal women.
Kanis JA; Cooper C; Rizzoli R; Reginster JY;
Osteoporos Int; 2019 Jan; 30(1):3-44. PubMed ID: 30324412
[TBL] [Abstract][Full Text] [Related]
53. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
54. Health-Related Quality of Life in Patients with Small Intestine Neuroendocrine Tumors.
Karppinen N; Lindén R; Sintonen H; Tarkkanen M; Roine R; Heiskanen I; Matikainen N; Schalin-Jäntti C
Neuroendocrinology; 2018; 107(4):366-374. PubMed ID: 30293074
[TBL] [Abstract][Full Text] [Related]
55. Nutrition and neuroendocrine tumors: An update of the literature.
Altieri B; Barrea L; Modica R; Muscogiuri G; Savastano S; Colao A; Faggiano A
Rev Endocr Metab Disord; 2018 Jun; 19(2):159-167. PubMed ID: 30267297
[TBL] [Abstract][Full Text] [Related]
56. Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
Wasiewicz T; Piotrowska A; Wierzbicka J; Slominski AT; Zmijewski MA
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200275
[TBL] [Abstract][Full Text] [Related]
57. Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.
Altieri B; Muscogiuri G; Paschou SA; Vryonidou A; Della Casa S; Pontecorvi A; Fassnacht M; Ronchi CL; Newell-Price J
Endocrine; 2018 Dec; 62(3):506-516. PubMed ID: 30073456
[TBL] [Abstract][Full Text] [Related]
58. Guidelines for the management of osteoporosis and fragility fractures.
Nuti R; Brandi ML; Checchia G; Di Munno O; Dominguez L; Falaschi P; Fiore CE; Iolascon G; Maggi S; Michieli R; Migliaccio S; Minisola S; Rossini M; Sessa G; Tarantino U; Toselli A; Isaia GC
Intern Emerg Med; 2019 Jan; 14(1):85-102. PubMed ID: 29948835
[TBL] [Abstract][Full Text] [Related]
59. Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy.
Hardy RS; Zhou H; Seibel MJ; Cooper MS
Endocr Rev; 2018 Oct; 39(5):519-548. PubMed ID: 29905835
[TBL] [Abstract][Full Text] [Related]
60. Supplementation of Vitamin D Deficiency in Patients with Neuroendocrine Tumors Using Over-the-Counter Vitamin D3 Preparations.
Robbins HL; Symington M; Mosterman B; Goodby J; Davies L; Dimitriadis GK; Kaltsas G; Randeva HS; Weickert MO
Nutr Cancer; 2018 Jul; 70(5):748-754. PubMed ID: 29781720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
